CEL-SCI Stock Discussion

$CEL-SCI (CVM.US)$
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
Wednesday, 23rd April at 8:30 am
• Concluded a successful meeting with Saudi Food and Drug Authority
• CEL-SCI was encouraged to apply for Conditional Approval with Breakthrough Therapy Designation based on data from its concluded Phase 3 study
• Evaluating Saudi Arabia-based partnerships to ...

$CEL-SCI (CVM.US)$ quite and under the radar

$CEL-SCI (CVM.US)$
Breakthrough Cancer Study: New Data Shows 306% Survival Boost for Multikine Treatment

$CEL-SCI (CVM.US)$
New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
Tuesday, 8th April at 9:51 am
Head and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall survival, suggesting pre-surgical tumor response is a strong indicator of efficacy and leads to improved overall survival
A third-p...

$CEL-SCI (CVM.US)$
Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients

$CEL-SCI (CVM.US)$
CEL-SCI Cancer Treatment Shows 73% Survival Rate, FDA Clears Path to Market

$CEL-SCI (CVM.US)$ it should pump when open

$CEL-SCI (CVM.US)$ let’s go🚀🚀🚀

$CEL-SCI (CVM.US)$
CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
Monday, 17th March at 8:00 am
Growing body of data on PD-L1 as a cancer biomarker spurs interest
Working towards partnership for non-dilutive funding of the final confirmatory head and neck cancer Registration Study
CEL-SCI Corporation (NYSE: CVM) today announced it received comments from the U.S. Food and Drug Administra...

$CEL-SCI (CVM.US)$
Major Breakthrough: JAMA Study Shows Multikine Triples Survival Rates in Head and Neck Cancer